U.S. Genetic Testing Market Size, Share, Growth Analysis, By Type (Predictive and Presymptomatic Testing, Carrier Testing), By Technique (Cytogenetic Testing and Chromosome Analysis, Biochemical Testing), By Application, By Payer, By End-User - Industry Forecast 2026-2033

Report ID: SQMIC35A2876 | Region: Country | Published Date: January, 2025
Pages: 165 |Tables: 67 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

FAQs

U.S. Genetic Testing Market size was valued at USD 6.03 Billion in 2024 and is poised to grow from USD 6.49 Billion in 2025 to USD 11.76 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026–2033).

The landscape reflects the presence of both established and up-and-coming players in the competitive setting. The two businesses Myriad Genetics and Quest Diagnostics that were the market leader. Due to its extensive genetic testing, Quest Diagnostics dominates the market portfolio with a variety of application areas, including autoimmune disorders, different disorders, as well as heart problems. Due to its existence, Myriad Genetics is anticipated to be the second largest firm in terms of market revenue share in technologically sophisticated goods. Some of Myriad's well-known product lines, EndoPredict and MyRisk are examples of genetics. In other businesses like BioReference, Ambry Genetics, and Invitae Corporation, the goal of laboratories is to keep their position supported by innovative product offerings. Strong investment activities are expected to support R&D endeavors to lead to the emergence of new players 'Natera (United States) ', 'Myriad Genetics (United States) ', 'Guardant Health (United States) ', '23andMe (United States) ', 'Color Genomics (United States) ', 'Fulgent Genetics (United States) ', 'GeneDx (United States) ', 'Pathway Genomics (United States) ', 'Progenity (United States) ', 'Sema4 (United States) ', 'Veracyte (United States) ', 'BioReference Laboratories (United States) ', 'Quest Diagnostics (United States) ', 'Labcorp (United States) ', 'Genomic Health (United States) '

Growing need for early and preventive care is one of the key factors influencing the growth of the U.S. genetic testing industry. Healthcare providers and governmental organizations are placing a larger emphasis on early detection and screening for health hazards as a result of the rising cost of treating diseases. The Centers for Disease Control and Prevention (CDC) estimate that the direct and indirect expenses of treating chronic illnesses like cardiovascular disease in the American healthcare system total USD 320 billion yearly.

The considerable and steady increase in insurance coverage of genetic tests for various types by major insurance companies is one of the most important trends in the U.S. genetic testing business. Many insurance providers are expanding their coverage to evaluate the effectiveness of mental medications. Psychiatric medications are notoriously difficult to fit the patient's symptoms. Due to this, many people who are now utilizing psychiatric medications use a trial-and-error system in an effort to find the best remedy for them successfully. For Instance, UnitedHealthcare, the biggest insurer in the United States, started extending insurance coverage beginning on October 1, 2019, for anyone aged over 27 plans, both private and public.

In terms of geography, North America led the global genetic testing market in terms of revenue in 2019 and is anticipated to continue to lead the market during the forecast period. This is explained by the majority of important actors being present in the region. However, due to increased affordability, a rise in healthcare spending, and increased awareness of early genetic condition screening, Asia-Pacific is anticipated to expand at the highest CAGR throughout the projection period.

U.S. Genetic Testing Market Size, Share, Growth Analysis, By Type (Predictive and Presymptomatic Testing, Carrier Testing), By Technique (Cytogenetic Testing and Chromosome Analysis, Biochemical Testing), By Application, By Payer, By End-User - Industry Forecast 2026-2033

To request a free sample copy of this report, please complete the form below.

Our Clients

FAQs

What is the global market size of U.S. Genetic Testing Market?

Who are the key vendors in the U.S. Genetic Testing Market?

What is the key driver of U.S. Genetic Testing Market?

What is the key market trend for U.S. Genetic Testing Market?

Which region accounted for the largest share in U.S. Genetic Testing Market?

$3,500